Mylan Pushes FDA To Rule On Ranbaxy's Lipitor ANDA

Law360, New York (March 21, 2011, 1:57 PM EDT) -- Mylan Pharmaceuticals Inc. is accusing the U.S. Food and Drug Administration of stalling on a decision that could give Ranbaxy Laboratories Ltd. exclusive rights to market a generic version of the cholesterol drug Lipitor, saying the delay could cost patients millions of dollars.

Mylan, which also wants to make a generic version of Lipitor, filed its lawsuit Friday in the U.S. District Court for the District of Columbia. It asks the court to require the FDA to strip India-based Ranbaxy of its eligibility for the exclusive...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.